


LISTING OF CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

Listing of Claims:

1. (previously presented) A method for treating a condition selected from the group consisting of skin requiring desquamation, nail disorders, calluses, and enlarged skin pore size, comprising contacting an area of affected skin with a composition having an effective amount of a halosalicylic acid compound of formula I,



wherein X is hydrogen or a cosmetically acceptable cation; R is hydrogen, C₁-C₁₈ alkyl or C₁-C₁₈ alkyl substituted with at least one Cl, Br, F or I group; and Y₁ and Y₂ are, independently, hydrogen, Cl, Br, F, I, methyl substituted by one to three Cl, Br, F, or I groups, phenyl, or phenyl substituted by at least one substituent selected from the group consisting of C₁-C₁₈ alkyl, Cl, Br, F and I; with the proviso that at least one of Y₁ and Y₂ is Cl, Br, F or I; and a cosmetically acceptable vehicle for the halosalicylic acid compound;

with the proviso that said area of skin is not affected by acne.

2. (previously presented) The method according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.001% to about 10% by weight, based on total weight of the composition.

3. (previously presented) The method according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.01% to about 5% by weight, based on total weight of the composition.

4. (previously presented) The method according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.1% to about 2.5% by weight, based on total weight of the composition.

5. (previously presented) The method according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.25% to about 2% by weight, based on total weight of the composition.

6. (previously presented) The method according to claim 1, wherein the compound of formula I is selected from the group consisting of 5-chlorosalicylic acid, 5-fluorosalicylic acid, 5-bromosalicylic acid, 5-iodosalicylic acid and mixtures thereof, or cosmetically acceptable salts thereof.

7. (previously presented) The method according to claim 1, wherein the compound of formula I is 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof.

8. (previously presented) The method according to claim 1, wherein the composition further contains salicylic acid.

9. (previously presented) The method according to claim 8, wherein the salicylic acid is present in an amount of 0.0625% to about 2% by weight, based on total weight of the composition, the halosalicylic acid compound is 5-chlorosalicylic acid, and the 5-chlorosalicylic acid is present in an amount of about 0.1% to about 2% by weight, based on total weight of the composition.

10. (previously presented) The method according to claim 1, wherein the composition further contains an RAR/RXR agonist.

11. (previously presented) The method according to claim 1, wherein the composition further contains a 5-alpha-reductase inhibitor.

12. (previously presented) The method according to claim 1, wherein the composition further contains an RAR/RXR agonist and a 5-alpha-reductase inhibitor.

13. (previously presented) The method according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.0001% to about 50% by weight, based on the total weight of the composition.

14. (previously presented) The method according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.01% to about 20% by weight, based on the total weight of the composition.

15. (previously presented) The method according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.5% to about 5% by weight, based on the total weight of the composition.

16. (previously presented) The method according to claim 11, wherein the 5-alpha-reductase inhibitor is present in an amount of about 0.01% to about 5% by weight, based on the total weight of the composition.

17. (previously presented) The method according to claim 11, wherein the 5-alpha-reductase inhibitor is present in an amount of about 0.1% to about 0.5% by weight, based on the total weight of the composition.

18. (previously presented) The method according to claim 10, wherein the RAR/RXR agonist is selected from the group consisting of phytol, isophytol, phytol derivatives, isophytol derivatives, retinoids, and mixtures thereof.

19. (previously presented) The method according to claim 10, wherein the RAR/RXR agonist is phytol, retinol or a mixture thereof.

20. (previously presented) The method according to claim 11, wherein the 5-alpha-reductase inhibitor is selected from the group consisting of oleanolic acid, saw palmetto, finasteride, and mixtures thereof.

21. (previously presented) The method according to claim 1, wherein the composition further contains an anti-aging active ingredient.


22. (withdrawn) The method of claim 1, wherein the condition is skin requiring desquamation.

23. (original) The method of claim 1, wherein the condition is enlarged skin pore size.

24. (previously presented) The method according to claim 23, wherein the compound of formula I is 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof.

25. (previously presented) The method according to claim 24, wherein the composition further comprises an antioxidant.

26. (withdrawn) A cosmetic composition comprising an effective amount of a halosalicylic acid compound of formula I,



wherein X is hydrogen or a cosmetically acceptable cation; R is hydrogen, C₁-C₁₈ alkyl or C₁-C₁₈ alkyl substituted with at least one Cl, Br, F or I group; and Y₁ and Y₂ are, independently, hydrogen, Cl, Br, F, I, methyl substituted by one to three Cl, Br, F, or I groups, phenyl, or phenyl substituted by at least one substituent selected from the group consisting of C₁-C₁₈ alkyl, Cl, Br, F, I.

F and I; with the proviso that at least one of Y₁ and Y₂ is Cl, Br, F or I; and a cosmetically acceptable vehicle for the halosalicylic acid compound.

27. (previously presented) A method for reducing the size of enlarged skin pores, comprising contacting an area of affected skin with a composition comprising an effective amount of 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, and a cosmetically acceptable vehicle; with the proviso that said area of skin is not affected by acne.

28. (previously presented) The method according to claim 27, wherein said 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, comprises from about 0.1% to about 2.5% by weight, based on total weight of the composition.

29. (previously presented) The method according to claim 28, wherein said 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, comprises from about 0.25% to about 2% by weight, based on total weight of the composition.

30. (previously presented) The method according to claim 28, wherein said composition further comprises a mattifying agent to minimize the color contrast between an enlarged pore and its surrounding skin.

31. (previously presented) The method according to claim 30, wherein said mattifying agent comprises dimethicone.

32. (previously presented) The method according to claim 28, wherein said composition further comprises an antioxidant.

33. (previously presented) The method according to claim 32, wherein said antioxidant has one or more thiol functions, in either reduced or non-reduced form.

34. (previously presented) The method according to claim 32, wherein the antioxidant is vitamin C.

35. (previously presented) The method according to claim 28, wherein said composition further comprises one or more anti-aging actives.

36. (previously presented) The method according to claim 35, wherein the anti-aging active is an alpha hydroxy acid.

37. (previously presented) The method according to claim 28, wherein the composition further comprises lactic acid, glycolic acid, or a combination thereof.

38. (previously presented) The method according to claim 28, wherein the composition further comprises an exfoliant selected from the group consisting of alpha hydroxyl acids, beta hydroxyl acids, keto acids, oxa acid, oxa diacid, and mixtures thereof.

39. (previously presented) The method according to claim 38, wherein the oxa acid is trioxundecanedioic acid.

40. (previously presented) The method according to claim 28, wherein the composition further comprises ascorbylphospheryl-cholesterol.

41. (previously presented) The method according to claim 28, wherein said composition further comprises a retinoid.

42. (previously presented) The method according to claim 1, wherein said condition is a nail disorder.

43. (previously presented) The method according to claim 1, wherein said condition is calluses.